Frequent PD-L1 expression in testicular germ cell tumors

British Journal of Cancer

Volumn 113, Issue 3, 2015, Pages 411-413

  Fankhauser, C D ^a   Curioni Fontecedro, A ^a   Allmann, V ^a   Beyer, J ^a   Tischler, V ^a   Sulser, T ^a   Moch, H ^a   Bode, P K ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY E1L3N; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER TISSUE; CHORIOCARCINOMA; CLINICAL EVALUATION; CONTROLLED STUDY; EMBRYONAL CARCINOMA; GERM CELL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRATUBULAR GERM CELL NEOPLASIA UNCLASSIFIED; MAJOR CLINICAL STUDY; MALE; NON SEMINOMATOUS GERMINOMA; PRECANCER AND CANCER-IN-SITU; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEMINOMA; STROMA CELL; TESTIS CELL; TESTIS TERATOMA; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; YOLK SAC TUMOR; ADOLESCENT; METABOLISM; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; PATHOLOGY; TESTICULAR NEOPLASMS; TESTIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; SEMINOMA; TESTICULAR NEOPLASMS; TESTIS; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 84938352808     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.244     Document Type: Article

References (10)

1. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, Koren-Michowitz M, Shimoni A, Nagler A (2008) Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 14(10): 3044-3051.
2. Bode PK, Barghorn A, Fritzsche FR, Riener MO, Kristiansen G, Knuth A, Moch H (2011) MAGEC2 is a sensitive and novel marker for seminoma: a tissue microarray analysis of 325 testicular germ cell tumors. Mod Pathol 24(6): 829-835.
3. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A, Rosso R, Zuber M, Muraro MG, Amicarella F, Cremonesi E, Heberer M, Iezzi G, Lugli A, Terracciano L, Sconocchia G, Oertli D, Spagnoli GC, Tornillo L (2013) Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 49(9): 2233-2242.
4. Faraj SF, Munari E, Guner G, Taube J, Anders R, Hicks J, Meeker A, Schoenberg M, Bivalacqua T, Drake C, Netto GJ (2015) Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. Urology 85(3): 703.e1-6.
5. Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26: 677-704.
6. Muenst S, Schaerli AR, Gao F, Däster S, Trella E, Droeser RA, Muraro MG, Zajac P, Zanetti R, Gillanders WE, Weber WP, Soysal SD (2014) Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 146(1): 15-24.
7. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng S-L, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515(7528): 558-562.
8. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Chen L, Zincke H, Blute ML, Leibovich BC, Kwon ED (2005) Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer 104(10): 2084-2091.
9. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10): 1020-1030.
10. Zhang Y, Kang S, Shen J, He J, Jiang L, Wang W, Guo Z, Peng G, Chen G, He J, Liang W (2015) Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) expression in epithelial-originated cancer: a meta-analysis. Medicine (Baltimore) 94(6): e515.